Sign In
Buy MBX
$62.00
-1.57 (-2.47%)
At Close: Jul 24, 2026
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey
05:49am, Friday, 17'th Jul 2026
MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both manufacturing companies, but which is the superior stock? We will compare
MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth
04:15pm, Monday, 13'th Jul 2026
CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)
08:38am, Monday, 06'th Jul 2026
I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables lon
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
10:43am, Friday, 12'th Jun 2026
MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide i
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
08:00am, Monday, 01'st Jun 2026
CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pre
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
03:18pm, Wednesday, 27'th May 2026
MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
08:00am, Tuesday, 26'th May 2026
CARMEL, Ind. and BURLINGTON, Mass.
Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript
02:31pm, Thursday, 14'th May 2026
Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
08:10pm, Monday, 11'th May 2026
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
03:09pm, Monday, 11'th May 2026
MBX Biosciences NASDAQ: MBX used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key devel
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
08:00am, Thursday, 07'th May 2026
Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Ma
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
07:00am, Thursday, 07'th May 2026
CARMEL, Ind. and BURLINGTON, Mass.
